Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Shotapharm | Pharma | 47.9% | 95th pct | 110 |
| GM Pharmaceuticals | Pharma | 33.6% | 81st pct | 110 |
| Aversi-Rational | Pharma | 17.8% | 55th pct | 110 |
| Neoparmi | Pharma | -2.0% | 12th pct | 110 |
| Bioparmi | Pharma | -8.3% | 5th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Shotapharm | GM Pharmaceuticals | Aversi-Rational | Neoparmi | Bioparmi |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 49.6% | 66.0% | 42.7% | 34.3% | 54.4% |
| EBITDA Margin | 47.9% | 33.6% | 17.8% | -2.0% | -8.3% |
| EBITDAR | 156,914 | 62,063 | 11,367 | 330 | -847 |
| EBITDAR Margin | 47.9% | 33.6% | 17.8% | 1.7% | -8.3% |
| EBIT Margin | 47.9% | 29.4% | 17.8% | -2.7% | -11.4% |
| Net Profit Margin | 47.9% | 32.1% | 16.4% | -3.1% | -12.6% |
| Operating Expense % of Sales | 1.7% | 32.4% | 24.9% | 36.2% | 62.8% |
| Returns | |||||
| Return on Assets (ROA) | 45.2% | 22.5% | 19.3% | -7.4% | -6.7% |
| Return on Equity (ROE) | 74.0% | 23.9% | 39.5% | -11.6% | -7.0% |
| ROIC [EBIT / Invested Capital] | |||||
| 77.2% |
| 27.0% |
| 43.1% |
| -10.8% |
| -6.9% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.01x | 0.00x | N/A | N/A |
| Equity-to-Assets | 61.0% | 94.2% | 48.9% | 63.7% | 95.3% |
| Net Debt | -8,614 | -46,609 | -131 | -264 | -1,264 |
| Cash & Equivalents | 8,614 | 47,348 | 131 | 264 | 1,264 |
| Total Debt | N/A | 738 | N/A | N/A | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 2.56x | 13.46x | 1.66x | 1.91x | 0.28x |
| Quick Ratio | 2.51x | 8.26x | 1.33x | 1.91x | 0.28x |
| Cash Ratio | 0.06x | 3.15x | 0.00x | 0.09x | 1.42x |
| Total Current Assets | 347,147 | 202,180 | 43,672 | 5,533 | 251 |
| Total Current Liabilities | 135,425 | 15,021 | 26,315 | 2,894 | 888 |
| Inventory | 7,354 | 78,109 | 8,627 | N/A | N/A |
| Trade Receivables | 331,449 | 67,384 | 34,244 | 242 | 3,828 |
| Trade Payables | 135,425 | 8,373 | 4,348 | 1,581 | 888 |
| Net Working Capital | 211,722 | 187,159 | 17,358 | 2,639 | -637 |
| Net Working Capital % of Revenue | 64.7% | 101.2% | 27.2% | 13.8% | -6.3% |
| Trade Working Capital | 203,378 | 137,121 | 38,523 | -1,338 | 2,939 |
| Trade Working Capital % of Revenue | 62.1% | 74.2% | 60.4% | -7.0% | 29.0% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | 22.43x | 0.81x | 4.24x | N/A | N/A |
| Days Inventory Outstanding (DIO) | 16.3 | 453.2 | 86.2 | N/A | N/A |
| Receivables Turnover | 0.99x | 2.74x | 1.86x | 79.16x | 2.65x |
| Days Sales Outstanding (DSO) | 369.5 | 133.0 | 196.0 | 4.6 | 137.6 |
| Payables Turnover | 1.22x | 7.51x | 8.41x | 7.98x | 5.21x |
| Days Payable Outstanding (DPO) | 299.7 | 48.6 | 43.4 | 45.7 | 70.1 |
| Cash Conversion Cycle | 86.1 days | 537.6 days | 238.7 days | -41.1 days | 67.5 days |
| Asset Turnover | 0.94x | 0.70x | 1.18x | 2.41x | 0.53x |
| Cash flow & dividends | |||||
| Operating Cash Flow | -973 | 10,288 | 4,732 | -289 | 7,425 |
| Free Cash Flow (OCF − Capex proxy) | -973 | 5,119 | 2,622 | -289 | 233 |
| Cash Conversion (OCF / EBITDA) | -0.6% | 16.6% | 41.6% | N/A | N/A |
| Dividends Declared | 87 | 0 | 5,770 | N/A | N/A |
| Dividend Payout Ratio | 0.1% | 0.0% | 55.1% | N/A | N/A |